Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BeBetter Med logo — Clinical-stage drug discovery and development of advanced no...

BeBetter Med

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other severe illnesses.

Founded 2012 China China 5 employees Private Equity Total: $499.00M Health Care, Pharmaceutical

General Information

Company Name BeBetter Med
Founded Year 2012
Location China China
Employees 5
Industries Health Care, Pharmaceutical
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with BeBetter Med. To contact BeBetter Med, visit bebettermed.cn.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BeBetter Med compare?

A PDF of BeBetter Med and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BeBetter Med soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BeBetter Med

BeBetter Med is a rapidly growing novel drug discovery and development company based in Guangzhou, China. Founded in 2012 by overseas returnees, the company is dedicated to creating advanced novel medicines for the treatment of cancer and other severe diseases. With a focus on clinical-stage drug discovery and development, BeBetter Med has positioned itself as a strong contender in the Health Care and Pharmaceutical industries. The company boasts a robust pipeline with eight innovative drug candidates, all with proprietary intellectual property rights. Notably, BEBT-908 has progressed to the pivotal phase II trial for the treatment of lymphoma, while BEBT-209 and BEBT-109 are in the phase Ib/II trial for breast cancer and lung cancer, respectively. This demonstrates BeBetter Med's commitment to tackling a varied spectrum of severe illnesses with its comprehensive pharmaceutical research capabilities extending from drug design and synthesis to clinical development. In November 2019, the company received a Venture Round investment from Lucky Source Funds, signifying external validation and support for its vision and capabilities. This investment underscores the confidence of industry stakeholders in BeBetter Med's potential to bring several new drugs to the market in the coming years. With a strong foundation and a promising portfolio, BeBetter Med presents an intriguing opportunity for investors seeking to participate in the advancement of cutting-edge treatments for critical medical conditions.

Business keywords: drug discovery, clinical-stage, novel medicines, cancer treatment, pharmaceutical research, oncology drugs, metabolic disease, clinical development, small molecule drugs, clinical trials, IP rights, Guangzhou, biopharmaceutical company, overseas returnees

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round CNY499.00M 2
Gaoxin Capital 盈科创新资产管理有限公司
Gaoxin Capital, 盈科创新资产管理有限公司
08 Oct 2021
Venture Round Undisclosed 2
前海长城基金管理(深圳)有限公司
前海长城基金管理(深圳)有限公司, Lucky Source Funds
15 Nov 2019

BeBetter Med Alternatives & Competitors

View All Alternatives
BeBetter Med vs
Tetralogic Pharmaceuticals
Tetralogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
BeBetter Med vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
BeBetter Med vs
Synta Pharmaceuticals
Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, includ...

Post-IPO Equity
Biotechnology, Health Care
View all alternatives

FAQ About BeBetter Med

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other severe illnesses.
BeBetter Med was founded in 2012.
BeBetter Med is headquartered in China.
BeBetter Med operates in Health Care and Pharmaceutical. Its work centres on drug discovery, clinical-stage, novel medicines and cancer treatment.
BeBetter Med has approximately 5 employees.
BeBetter Med has completed 2 funding rounds, raising a total of $499.00M. The latest funding stage is Private Equity.
Top alternatives and competitors to BeBetter Med include Tetralogic Pharmaceuticals, Redx Pharma, Synta Pharmaceuticals, Pacylex Pharmaceuticals, Inc., Apollomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BeBetter Med and Tetralogic Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BeBetter Med, https://bouncewatch.com/company/bebetter-med, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout